mikkelwilliam Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) achieved history in March by garnering US FDA approval for Rezdiffra (resmetirom), the first drug specifically indicated for nonalcoholic steatohepatitis (NASH). On April 9, 2024, MDGL announced the availability of Rezdiffra meaning the launch of this first-to-market drug is now underway. In this article, I consider the prospects of the drug and the expectations I think the market might have. The approval and the market MDGL's Rezdiffra is approved ...